Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EORTC CLTF 2021 | The future of CTCL therapy

Julia Jane Scarisbrick • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Antibodies Brentuximab vedotin Chlormethine Mogamulizumab

Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, shares her views on the future of cutaneous T-cell lymphoma (CTCL) therapy, highlighting the unmet need for more efficacious therapies and to determine the optimal sequencing of therapies. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Julia Jane Scarisbrick

PROCLIPI: identification of key prognostic factors in CTCL 0:59
PROCLIPI: identification of key prognostic factors in CTCL
Julia Jane Scarisbrick • 15 Oct 2021
MAVORIC: mogamulizumab improves PFS for CTCL 0:59
MAVORIC: mogamulizumab improves PFS for CTCL
Julia Jane Scarisbrick • 15 Oct 2021
ALCANZA: brentuximab vedotin improves ORR and PFS in CTCL 0:46
ALCANZA: brentuximab vedotin improves ORR and PFS in CTCL
Julia Jane Scarisbrick • 15 Oct 2021
The role of transplant in CTCL 1:10
The role of transplant in CTCL
Julia Jane Scarisbrick • 15 Oct 2021

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals